Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1293086rdf:typepubmed:Citationlld:pubmed
pubmed-article:1293086lifeskim:mentionsumls-concept:C0025664lld:lifeskim
pubmed-article:1293086lifeskim:mentionsumls-concept:C1415576lld:lifeskim
pubmed-article:1293086lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:1293086lifeskim:mentionsumls-concept:C0085155lld:lifeskim
pubmed-article:1293086lifeskim:mentionsumls-concept:C1546805lld:lifeskim
pubmed-article:1293086pubmed:issue4lld:pubmed
pubmed-article:1293086pubmed:dateCreated1993-4-8lld:pubmed
pubmed-article:1293086pubmed:abstractTextHLA-DRB1 allelic specificities can be determined using SSOs annealing to their complementary PCR-amplified target DNA. To perform HLA-DR oligotyping routinely for donors and recipients of bone marrow transplantation, a "reverse" dot-blot technique has been developed that consists in the hybridization of labeled PCR-amplified target DNA to SSOs that have been first attached to nitrocellulose membranes. The 15 oligonucleotides chosen enabled the following HLA-DRB1 "generic" specificities to be defined: DR1, BON, 2, 3, 4, 11, 11 JVM, 12, 13, 13 HAG, 14, 7, 8, 9, 10. The genomic DNA was amplified by asymetric PCR with incorporation of biotinylated deoxynucleotides predominantly to generate labeled single-stranded DNA. Hybridization between specific immobilized oligoprobes and target DNA was nonradioactively detected by a colorimetric reaction using alkaline phosphatase. The reverse dot-blot methodology was successfully tested, first, for the determination of HLA-DR4 subspecificities, and then the procedure was routinely applied to the generic HLA-DR oligotyping of bone-marrow donors and recipients.lld:pubmed
pubmed-article:1293086pubmed:languageenglld:pubmed
pubmed-article:1293086pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:citationSubsetIMlld:pubmed
pubmed-article:1293086pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293086pubmed:statusMEDLINElld:pubmed
pubmed-article:1293086pubmed:monthDeclld:pubmed
pubmed-article:1293086pubmed:issn0198-8859lld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:NicolasJ CJClld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:ClotJJlld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:EliaouJ FJFlld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:PalmadeFFlld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:AvinensOOlld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:EdouardEElld:pubmed
pubmed-article:1293086pubmed:authorpubmed-author:BallaguerPPlld:pubmed
pubmed-article:1293086pubmed:issnTypePrintlld:pubmed
pubmed-article:1293086pubmed:volume35lld:pubmed
pubmed-article:1293086pubmed:ownerNLMlld:pubmed
pubmed-article:1293086pubmed:authorsCompleteYlld:pubmed
pubmed-article:1293086pubmed:pagination215-22lld:pubmed
pubmed-article:1293086pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:meshHeadingpubmed-meshheading:1293086-...lld:pubmed
pubmed-article:1293086pubmed:year1992lld:pubmed
pubmed-article:1293086pubmed:articleTitleGeneric HLA-DRB1 gene oligotyping by a nonradioactive reverse dot-blot methodology.lld:pubmed
pubmed-article:1293086pubmed:affiliationLaboratory of Immunology, Saint Eloi Hospital, CHU Montpellier, France.lld:pubmed
pubmed-article:1293086pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1293086pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed